Mandate

Vinge has advised Cell Impact in connection with its rights issue

December 06, 2023

Vinge has advised Cell Impact AB (publ) in connection with a partly guaranteed rights issue which will provide Cell Impact with issue proceeds of SEK 129 million before deduction of transaction costs

Cell Impact is a global supplier of advanced flow plates to fuel cell and electrolyzer manufacturers. The company has developed and patented a unique method for high velocity forming, Cell Impact Forming™ which is significantly more scalable and cost-efficient compared to conventional forming methods.

Vinge’s team consisted of Johan Larsson, Dain Hård Nevonen, Rikard LindahlStina Bengtsson, Anna Svensson and Elias Kröger.

Related

Vinge advises Cinclus Pharma in connection with listing on Nasdaq Stockholm

Vinge advises Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) in connection with an offering of new ordinary shares and listing on Nasdaq Stockholm. The first day of trading is 20 June 2024.
June 20, 2024

Vinge advises Axcel VI and the Currentum in connection with the acquisition of Elektro-Emanuel

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elektro-Emanuel AB. The company carries out electrical installations for both companies and private individuals and has offices in four cities in western Sweden.
June 19, 2024

Vinge has advised the lead investor ARCH Venture Partners in Moleculent’s $26 million Series A financing

Moleculent AB, a company pioneering technology to study the communication between cells in human tissue, has closed its oversubscribed $26 million Series A financing. The round was led by ARCH Venture Partners and co-led by Eir Ventures with participation from the company’s existing investors.
June 19, 2024